UCB Announces Positive Phase 3 Study Results for Fenfluramine in Treating CDKL5 Deficiency Disorder UCB has revealed promising findings from the GEMZ phase 3 trial, demonstrating that fenfluramine significantly lessens seizure frequency in patients with CDKL5 deficiency disorder.

UCB Announces Positive Phase 3 Study Results for Fenfluramine in Treating CDKL5 Deficiency Disorder #United_States #Atlanta #UCB #fenfluramine #CDKL5_Deficiency

UCB Unveils Positive Findings from GEMZ Phase 3 Study on Fenfluramine for Seizures UCB revealed promising results from its GEMZ Phase 3 study, showing fenfluramine effectively reduces seizure frequency in patients with CDKL5 Deficiency Disorder.

UCB Unveils Positive Findings from GEMZ Phase 3 Study on Fenfluramine for Seizures #USA #Atlanta #fenfluramine #CDKL5_Deficiency #GEMZ_Study